Navigation Links
Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Date:11/9/2009

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new therapies will drive sales of HER2-targeting agents to grow by 3.3 percent per year from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant declines in sales in the hormonal therapy and chemotherapy segments of the market will be offset by a 1.2 percent annual increase in breast cancer incidence in the world's major markets and by the launch and uptake of premium-priced agents. Emerging HER2-targeting therapies that are expected to launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in metastatic breast cancer, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where there is a significant need for effective therapeutic options," said Decision Resources Analyst Niamh Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in Europe, are not very enthusiastic about Avastin for breast cancer because they consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake of a novel class of breast cancer therapies -- the poly ADP-ribose polymerase (PARP) inhibitors. The PARP inhibitors represent a novel therapeutic strategy in DNA-repair-deficient tumors, such as triple-negative breast cancer.

"PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's olaparib, could dramatically improve prognoses for the woefully underserved patient subgroups with DNA-repair-deficient tumors," Dr. Murphy said.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563
    ccomfort@dresources.com       emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
3. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
4. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
5. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
6. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
7. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
8. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
9. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 28, 2016 , ... May 26, 2016- In search of the K. Warriors, ... event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 ... sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer ... timber frame barn kits, which can be found on its website at SouthlandLogHomes.com. , ... barn plans, and they highlight the craftsmanship of timber post and beam construction. ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. ... today that it has been recognized as one of the best small businesses for ... named as one of nine small businesses providing progressive benefits to new parents on ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
Breaking Medicine News(10 mins):